Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women.
The intake of long-chain n-3 PUFA, including DHA (22 : 6n-3), is associated with a reduced risk of CVD. Schizochytrium sp. are an important primary source of DHA in the marine food chain but they also provide substantial quantities of the n-6 PUFA docosapentaenoic acid (22 : 5n-6; DPA). The effect of this oil on cardiovascular risk factors was evaluated using a double-blind randomised placebo-controlled parallel-design trial in thirty-nine men and forty women. Subjects received 4 g oil/d for 4 weeks; the active treatment provided 1.5 g DHA and 0.6 g DPA. Active treatment increased plasma concentrations of arachidonic acid, adrenic acid, DPA and DHA by 21, 11, 11 and 88 mg/l respectively and the proportions of DPA and DHA in erythrocyte phospholipids by 78 and 27 % respectively. Serum total, LDL- and HDL-cholesterol increased by 0.33 mmol/l (7.3 %), 0.26 mmol/l (10.4 %) and 0.14 mmol/l (9.0 %) compared with placebo (all P < or =0.001). Factor VII (FVII) coagulant activity increased by 12 % following active treatment (P = 0.006). There were no significant differences between treatments in LDL size, blood pressure, plasma glucose, serum C-reactive protein, plasma FVII antigen, FVII activated, fibrinogen, von Willebrand factor, tocopherol or carotenoid concentrations, plasminogen activator inhibitor-1, creatine kinase or troponin-I activities, haematology or liver function tests or self-reported adverse effects. Overall, the oil was well tolerated and did not adversely affect cardiovascular risk.
Sanders
Thomas A B
TA
Nutritional Sciences Research Division, Franklin-Wilkins Building, King's College London, UK. Tom.Sanders@kcl.ac.uk
Gleason
Kelly
K
Griffin
Bruce
B
Miller
George J
GJ
D000328:Adult; D001794:Blood Pressure / Q000502:physiology; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000097:blood; D004311:Double-Blind Method; D004912:Erythrocytes / Q000737:chemistry; D056890:Eukaryota / Q000737:chemistry*; D005167:Factor VII / Q000032:analysis; D005227:Fatty Acids / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D010743:Phospholipids / Q000737:chemistry; D012307:Risk Factors; D014280:Triglycerides / Q000008:administration & dosage* / Q000737:chemistry
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D010743:Phospholipids; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D005167:Factor VII; D002097:C-Reactive Protein; D002784:Cholesterol; C026219:docosapentaenoic acid